Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.04 USD | +0.62% | -6.14% | -8.21% |
05-01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
04-30 | Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.21% | 6.38B | |
+9.37% | 106B | |
+0.52% | 104B | |
+6.72% | 23.25B | |
-13.26% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-11.77% | 16.99B | |
+8.39% | 14.26B | |
+37.74% | 12.76B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Exelixis Seeks to Block Generic Version of Kidney Cancer Drug